An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers.

Prior treatment

• Has received a blood transfusion (except for autologous blood transfusion) within the first two months prior to participating the trial
• Has taken gene therapy within one year prior to participating the trial
• Has any vaccinations within 3 months prior to blood sample collection

Other illness

• Has any history of cancer diagnosis

Lab values

• Has any severe acute or uncontrolled chronic lung disease such as pneumonia, lung abscess, acute exacerbation of COPD or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of Study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this Study

Other

• Is participating in a clinical trial (the non-intervention trial will be accepted)
• Is currently pregnant

• Female or male participants at least 18 years of age
• Participants in the test group must have identified lung nodules or masses through low-dose computed tomography (LDCT)CT scan, and have a scheduled medical operation, which is not limited to surgical excision. Control group participants should have no significant findings in LDCT/CT scan displaying either no nodules, or nodules smaller than 6mm were assessed by investigators without clinically significant justification, through an axial resolution of 3 mm or less, within 2 months prior to their enrollment in the study.
• Participants in the test group should be treatment naïve.
• Ability to complete a questionnaire, comprehend and comply with the requirements of the study
• Written informed consent, and authorization to use and disclose health information